Ann D. Thor

University of Colorado Anschutz Medical Campus — United States

Medicine · Health Sciences

76h-index22.8kcitations298works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(76), Monoclonal and Polyclonal Antibodies Research(63), Breast Cancer Treatment Studies(34), Cancer-related Molecular Pathways(34), Metabolism, Diabetes, and Cancer(34)

Publications298 total

Abstract PO1-24-08: Targeting of HER3 potentiates the antitumor activity of paclitaxel against triple negative breast cancer
Cancer Research·2024
Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer
Cell Cycle·2023· 5 citedOpen Access
HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
Cancer Cell International·2023· 13 citedOpen Access
Supplemental Figure 3 from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Data from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Supplemental Figure 2 from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Supplemental Figure 1 from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Supplemental Figure 2 from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Supplemental Table 1 from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Supplemental Figure 3 from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Data from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Supplemental Table 1 from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Supplemental Figure 1 from Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression <i>In Vivo</i>
2023Open Access
Gender differences in appointments to pathology department interim chair positions and subsequent advancement to permanent chair positions
Academic Pathology·2023· 3 citedOpen Access
Data from Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
2023Open Access
Data from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
2023Open Access
Supplementary Data from Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
2023Open Access
Data from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
2023Open Access
Supplementary Data from Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
2023Open Access
Supplementary Data from Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Susan M. Edgerton(14), Jeffrey Schlom(8), Dan H. Moore(7), Bolin Liu(7), Donald A. Berry(6), Daniel F. Hayes(6), Raffaella Muraro(5), David L. Page(4), Donald L. Weaver(4), S M Edgerton(4), Helene S. Smith(4), Zeying Fan(4), Stuart E. Lind(4), Noriaki Ohuchi(4), Patricia Horan Hand(4), Xiaohe Yang(4), D. Wunderlich(4), Craig Allred(3), Gary M. Clark(3), Stephen B. Edge(3)